Compare Stocks: VTYX, TNGX, ELVN, and AMLX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$32.41 -4.5%	$27.21	$10.83 ▼ $41.14	$3.61B	-0.13	1.91 million shs	2.05 million shs
ELVN Enliven Therapeutics	$49.45 -1.6%	$56.43	$14.78 ▼ $62.32	$3.62B	0.3	1.02 million shs	6.01 million shs
TNGX Tango Therapeutics	$21.75 -7.4%	$25.65	$6.69 ▼ $34.39	$3.67B	1.12	2.17 million shs	6.24 million shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+2.50%	-18.28%	+106.83%	+153.80%
ELVN Enliven Therapeutics	0.00%	-8.97%	-16.07%	+9.65%	+159.99%
TNGX Tango Therapeutics	0.00%	-8.54%	-7.49%	-22.24%	+185.43%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+506.06%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMLX Amylyx Pharmaceuticals	$32.41 -4.5%	$27.21	$10.83 ▼ $41.14	$3.61B	-0.13	1.91 million shs	2.05 million shs
ELVN Enliven Therapeutics	$49.45 -1.6%	$56.43	$14.78 ▼ $62.32	$3.62B	0.3	1.02 million shs	6.01 million shs
TNGX Tango Therapeutics	$21.75 -7.4%	$25.65	$6.69 ▼ $34.39	$3.67B	1.12	2.17 million shs	6.24 million shs
VTYX Ventyx Biosciences	$14.00	$13.98	$0.78 ▼ $25.00	$1.00B	1.26	3.32 million shs	5.45 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMLX Amylyx Pharmaceuticals	0.00%	+2.50%	-18.28%	+106.83%	+153.80%
ELVN Enliven Therapeutics	0.00%	-8.97%	-16.07%	+9.65%	+159.99%
TNGX Tango Therapeutics	0.00%	-8.54%	-7.49%	-22.24%	+185.43%
VTYX Ventyx Biosciences	0.00%	0.00%	0.00%	0.00%	+506.06%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMLX Amylyx Pharmaceuticals	3.00	Buy	$38.86	19.89% Upside
ELVN Enliven Therapeutics	2.78	Moderate Buy	$75.00	51.67% Upside
TNGX Tango Therapeutics	2.75	Moderate Buy	$43.46	99.82% Upside
VTYX Ventyx Biosciences	1.89	Reduce	$14.00	N/A

Current Analyst Ratings Breakdown

Latest VTYX, TNGX, ELVN, and AMLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$55.00 ➝ $57.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $55.00
8/19/2026	AMLX Amylyx Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$28.00 ➝ $52.00
8/18/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$30.00 ➝ $42.00
8/18/2026	AMLX Amylyx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $55.00
8/18/2026	ELVN Enliven Therapeutics	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform
8/18/2026	ELVN Enliven Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
8/18/2026	ELVN Enliven Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$62.00 ➝ $73.00
8/18/2026	TNGX Tango Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$66.00 ➝ $68.00
8/17/2026	AMLX Amylyx Pharmaceuticals	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/17/2026	AMLX Amylyx Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $30.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMLX Amylyx Pharmaceuticals	$87.37M	41.33	N/A	N/A	$2.78 per share	11.66
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
TNGX Tango Therapeutics	$62.38M	58.79	N/A	N/A	$2.57 per share	8.46
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	$3.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMLX Amylyx Pharmaceuticals	-$144.74M	-$1.43	N/A	N/A	N/A	N/A	-52.92%	-48.53%	11/5/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
TNGX Tango Therapeutics	-$101.59M	-$0.85	N/A	N/A	N/A	N/A	-25.75%	-23.36%	11/3/2026 (Estimated)
VTYX Ventyx Biosciences	-$135.12M	-$1.50	N/A	N/A	N/A	N/A	-48.11%	-43.89%	N/A

Latest VTYX, TNGX, ELVN, and AMLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	TNGX Tango Therapeutics	-$0.3172	-$0.37	-$0.0528	-$0.37	$1.56 million	N/A
8/6/2026	Q2 2026	AMLX Amylyx Pharmaceuticals	-$0.3609	-$0.39	-$0.0291	-$0.39	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMLX Amylyx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
TNGX Tango Therapeutics	N/A	N/A	N/A	N/A	N/A
VTYX Ventyx Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMLX Amylyx Pharmaceuticals	N/A	12.12	12.12
ELVN Enliven Therapeutics	N/A	64.07	64.07
TNGX Tango Therapeutics	N/A	50.82	50.82
VTYX Ventyx Biosciences	N/A	17.86	17.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMLX Amylyx Pharmaceuticals	95.84%
ELVN Enliven Therapeutics	95.08%
TNGX Tango Therapeutics	78.99%
VTYX Ventyx Biosciences	97.88%

Insider Ownership

Company	Insider Ownership
AMLX Amylyx Pharmaceuticals	10.90%
ELVN Enliven Therapeutics	3.00%
TNGX Tango Therapeutics	6.50%
VTYX Ventyx Biosciences	14.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMLX Amylyx Pharmaceuticals	136	111.42 million	99.28 million	Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
TNGX Tango Therapeutics	137	168.61 million	157.65 million	Optionable
VTYX Ventyx Biosciences	30	71.76 million	61.36 million	Optionable

VTYX, TNGX, ELVN, and AMLX Headlines

Recent News About These Companies

Ventyx Biosciences Shareholders Approve Merger With Eli Lilly

June 12, 2026 | theglobeandmail.com

Ventyx Biosciences, Inc. Investigated by the Portnoy Law Firm

April 29, 2026 | globenewswire.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

February 5, 2026 | businesswire.com

Assessing Ventyx Biosciences (VTYX) Valuation After Sharp Share Price Momentum And A High P/B Multiple

January 26, 2026 | finance.yahoo.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 23, 2026 | prnewswire.com

Halper Sadeh LLC Encourages VTYX and SNCY Shareholders to Contact the Firm to Discuss Their Rights

January 21, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, PEN, CWAN Shareholders to Contact the Firm to Discuss Their Rights

January 15, 2026 | caledonianrecord.comC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 15, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 13, 2026 | globenewswire.com

Halper Sadeh LLC Encourages VTYX, ONTF, FFIC, OCFC Shareholders to Contact the Firm to Discuss ...

January 13, 2026 | caledonianrecord.comC

LifeSci Capital Sticks to Its Hold Rating for Ventyx Biosciences (VTYX)

January 12, 2026 | theglobeandmail.com

UBS downgrades Ventyx Biosciences (VTYX)

January 10, 2026 | msn.com

Oppenheimer downgrades Ventyx Biosciences (VTYX)

January 9, 2026 | msn.com

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces an Investigation of Ventyx Biosciences, Inc. (NASDAQ: VTYX) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

January 8, 2026 | prnewswire.com

Lilly confirms bid to acquire Ventyx Biosciences

January 8, 2026 | thepharmaletter.comT

Canaccord Genuity downgrades Ventyx Biosciences (VTYX)

January 8, 2026 | msn.com

SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Ventyx Biosciences, Inc. (VTYX)

January 8, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ventyx Biosciences, Inc. - VTYX

January 8, 2026 | prnewswire.com

VTYX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Ventyx Biosciences, Inc. is Fair to Shareholders

January 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TNGX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

$32.41 -1.53 (-4.51%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$33.18 +0.78 (+2.39%)

As of 09/18/2026 07:53 PM Eastern

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx's research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

Enliven Therapeutics NASDAQ:ELVN

$49.45 -0.79 (-1.57%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$49.46 +0.00 (+0.01%)

As of 09/18/2026 07:40 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Tango Therapeutics NASDAQ:TNGX

$21.75 -1.74 (-7.41%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$21.74 -0.02 (-0.07%)

As of 09/18/2026 07:59 PM Eastern

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.

Ventyx Biosciences NASDAQ:VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, TNGX, ELVN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, TNGX, ELVN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, TNGX, ELVN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TNGX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Enliven Therapeutics NASDAQ:ELVN

Tango Therapeutics NASDAQ:TNGX

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VTYX, TNGX, ELVN, and AMLX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VTYX, TNGX, ELVN, and AMLX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VTYX, TNGX, ELVN, and AMLX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTYX, TNGX, ELVN, and AMLX Company Descriptions

Amylyx Pharmaceuticals NASDAQ:AMLX

Enliven Therapeutics NASDAQ:ELVN

Tango Therapeutics NASDAQ:TNGX

Ventyx Biosciences NASDAQ:VTYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools